AstraZeneca and Daiichi Sankyo Enhertu: CHMP Recommends Approval In The EU For Patients With HER2-low or HER2-Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy
AstraZeneca and Daiichi Sankyo Enhertu: CHMP Recommends Approval In The EU For Patients With HER2-low or HER2-Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy
Impacting News March 4, 2025
AstraZeneca and Daiichi Sankyo
AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) (trastuzumab deruxtecan) has been recommended for approval in . . .
This content is for paid subscribers.
Please click
here to subscribe or
here to log in.
Impacting News
March 4, 2025
